Advertisement

Topics

Safety and Pharmacokinetics Study of DWC20155 and DWC20156 in Healthy Subjects

2016-11-03 08:08:21 | BioPortfolio

Summary

The purpose of this study to Compare the safety and pharmacokinetics between co-administration and fixed dose combination of DWC20155 and DWC20156 in healthy subjects

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Conditions

Healthy

Intervention

Co-administration of DWC20155 and DWC20156, DWJ1366 Tab.

Location

Busan Paik Hospital
Busan
Korea, Republic of

Status

Not yet recruiting

Source

Daewoong Pharmaceutical Co. LTD.

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-11-03T08:08:21-0400

Clinical Trials [653 Associated Clinical Trials listed on BioPortfolio]

Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20163 in Healthy Volunteers

A randomized, open label, crossover study to explore drug-drug interactions between DWC20155 / DWC20156 and DWC20163 in Healthy Volunteers

Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20162 in Healthy Volunteers

A randomized, open label, crossover study to explore drug-drug interactions between DWC20155 / DWC20156 and DWC20162 in Healthy Volunteers

Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20161 in Healthy Volunteers

A randomized, open label, crossover study to explore drug-drug interactions between DWC20155 / DWC20156 and DWC20161 in Healthy Volunteers

Safety and Pharmacokinetics Study of Fixed Dose Combination of DWJ1386 Compared With Co-administration of DWC20155 and DWC20156 in Healthy Subjects

The purpose of this study is to compare the safety and pharmacokinetics between co-administration and fixed dose combination of DWC20155 and DWC20156 in healthy subjects

A Randomized, Open-label, Oral Dose, Crossover Study to Explore Drug-drug Interactions Between DWC20155 and DWC20156 in Healthy Subjects

A randomized, open-label, oral dose, crossover study to explore drug-drug interactions between DWC20155 and DWC20156 in healthy subjects.

PubMed Articles [7976 Associated PubMed Articles listed on BioPortfolio]

Pharmacokinetics and Safety of Single and Multiple Doses of Rasagiline in Healthy Japanese and Caucasian Subjects.

As of March 2018, rasagiline is approved for the treatment of Parkinson disease in 55 countries including Japan. The present study evaluated the pharmacokinetics (PK) and safety of rasagiline in healt...

Quantitation of anti-Pythium insidiosum antibodies before and after administration of an immunotherapeutic product to healthy dogs.

OBJECTIVE To evaluate the effect of an immunotherapeutic product on concentrations of anti-Pythium insidiosum antibodies in dogs. ANIMALS 7 healthy hound-crossbreds. PROCEDURES Antibody concentrations...

Effects of the Administration of Probiotics on Fecal Microbiota Diversity and Composition in Healthy Individuals.

Probiotics are expected to modify the composition of gut microbiota. We aimed to investigate the changes in the composition and diversity of gut microbiota by the administration of probiotics in healt...

Effect of one and two months high dose alpha-linolenic acid treatment on C-labeled alpha-linolenic acid incorporation and conversion in healthy subjects.

We aimed at identifying (1) the most sensitive compartment among plasma phospholipids, erythrocytes and LDL for studying ALA conversion, and (2) whether ALA incorporation and conversion is saturable a...

Oral administration of 5-aminolevulinic acid induces heme oxygenase-1 expression in peripheral blood mononuclear cells of healthy human subjects in combination with ferrous iron.

Heme oxygenase-1 (HO-1) is a major anti-inflammatory enzyme and a key regulator that induces immune tolerance through affecting the differentiation of dendritic cells. The aim of this study is to dete...

Medical and Biotech [MESH] Definitions

Administration of a drug or chemical by the individual under the direction of a physician. It includes administration clinically or experimentally, by human or animal.

Healthy People Programs are a set of health objectives to be used by governments, communities, professional organizations, and others to help develop programs to improve health. It builds on initiatives pursued over the past two decades beginning with the 1979 Surgeon General's Report, Healthy People, Healthy People 2000: National Health Promotion and Disease Prevention Objectives, and Healthy People 2010. These established national health objectives and served as the basis for the development of state and community plans. These are administered by the Office of Disease Prevention and Health Promotion (ODPHP). Similar programs are conducted by other national governments.

The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example.

Governmental guidelines and objectives pertaining to public food supply and nutrition including recommendations for healthy diet and changes in food habits to ensure healthy diet.

The administration of drugs through the nasal passage.

More From BioPortfolio on "Safety and Pharmacokinetics Study of DWC20155 and DWC20156 in Healthy Subjects"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial